Potential first sales from 2023 "Imagion intends to sell MagSense on a ‘printer and ink’ model where a low sales price for the SQUID equipment (US$0.5m at a 50% gross margin) is matched with a relatively higher selling price for the nanoparticles (US$1,500 per test for an 80% gross margin).
Pitt Street Research argues that, potentially, Imagion can look to make its commercial launch in 2022 or 2023.
Imagion is undervalued on our numbers We value Imagion at 12 cents base case and 26 cents optimistic case on a risk weighted DCF basis. We see Imagion being re-rated towards our valuation range on the back of improved sentiment towards MagSense as a Breakthrough Device, as the company takes the device into the clinic."
News 
Market Data 
Discover 
